Who
Steven L. Hoerter
President and CEO
Company insider
Files Form 4 as: President and CEO, MBX Biosciences; Director, C4 Therapeutics; Director, Oric Pharmaceuticals; President and CEO, Deciphera Pharmaceuticals; Director, Constellation Pharmaceuticals; Chief Commercial Officer, Agios Pharmaceuticals; Director, Ignyta; Officer, Clovis Oncology.
In numbers
- Trades disclosed
- 150
- Buys
- 1
- Sells
- 19
- Bought
- $265K
- Sold
- $9.4M
- Companies
- 8
- Companies where not an officer
- 4
- First trade
- 1 Mar 2012
- Last trade
- 3 Aug 2026
- Last filed
- 4 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 4 Aug 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Code A | —71,000 at $0.00 | filing |
| 3 Aug 2026filed 4 Aug 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —331,000 at $0.00 | filing |
| 3 Aug 2026filed 4 Aug 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —331,000 at $0.00 | filing |
| 3 Aug 2026filed 4 Aug 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Code A | —71,000 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | CCCC C4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,000 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | CCCC C4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Code A | —11,938 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,249 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,249 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Code A | —11,938 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 22 Nov 2025filed 22 Apr 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —0 at $0.00 | filing |
| 22 Nov 2025filed 22 Apr 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —0 at $0.00 | filing |
| 22 Nov 2025filed 25 Nov 2025 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 6 Nov 2025filed 22 Apr 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,751 at $0.00 | filing |
| 6 Nov 2025filed 22 Apr 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,751 at $0.00 | filing |
| 6 Nov 2025filed 7 Nov 2025 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
News
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Gets Price Target Reduction from Truist FinancialAGIO · themarketsdaily.com · 10 Oct 2026Incyte (NASDAQ:INCY) & Agios Pharmaceuticals (NASDAQ:AGIO) Critical ContrastAGIO · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name Steven L. Hoerter; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.